학술논문
Determining the Sustained Virologic Response of Declatasvir in Egyptian Patients With Hepatitis C Virus Genotype 4
Document Type
Report
Author
Source
Jensen D, Sherman KE, Hezode C, Pol S, Zeuzem S, de Ledghen V, Tran A, Elkhashab M, Younes ZH, Kugelmas M, Mauss S, Everson G, Luket V, Vrlg J, Serfaty L, Brunetto M, Heo J, Bernste D, McPhee F, Hennken D, Mendez P, Hughes E, Novllo S; HALLMARK-QUAD Study Team. Daclatasv and asunaprev plus pegterferon alfa and rav HCV genotype 1 or 4 non-responders. J Hepatol. 2015 Jul;63(1):30-7. do 10.1016/j.jhep.2015.02.018. Epub 2015 Feb 19.
Hezode C, Alr L, Brown A, Hassane T, Rzetto M, ButM, Bourlre M, Thabut D, Mola E, RustgV, Samuel D, McPhee F, L Z, Y PD, Hughes E, Treel M; COMMAND-4 study team. Randomed controlled trl of the NS5A hor daclatasv plus pegylated terferon and rav for HCV genotype-4 (COMMAND-4). Ant Ther. 2015 Aug 27;21(3):195-205. do 10.3851/P2985. Onle ahead of prt.
Wyles DL, Ruane PJ, SulkowskMS, Dterh D, Luetkemeyer A, Morgan TR, Sherman KE, Dretler R, Fhbe D, Gathe JC Jr, Henn S, Hestrosa F, Huynh C, McDonald C, Mls A, Overton ET, Ramgopal M, Rashbaum B, Ray G, Scarsella A, Yozvk J, McPhee F, L Z, Hughes E, Y PD, Novllo S, Ackerman P; ALLY-2 vestators. Daclatasv plus Sofosbuv for HCV Patnts Cofected wh H-1. N Engl J Med. 2015 Aug 20;373(8):714-25. do 10.1056/NEJMoa1503153. Epub 2015 Jul 21.
Determining the Sustained Virologic Response of Declatasvir in Egyptian Patients With Hepatitis C Virus Genotype 4
Hezode C, Alr L, Brown A, Hassane T, Rzetto M, ButM, Bourlre M, Thabut D, Mola E, RustgV, Samuel D, McPhee F, L Z, Y PD, Hughes E, Treel M; COMMAND-4 study team. Randomed controlled trl of the NS5A hor daclatasv plus pegylated terferon and rav for HCV genotype-4 (COMMAND-4). Ant Ther. 2015 Aug 27;21(3):195-205. do 10.3851/P2985. Onle ahead of prt.
Wyles DL, Ruane PJ, SulkowskMS, Dterh D, Luetkemeyer A, Morgan TR, Sherman KE, Dretler R, Fhbe D, Gathe JC Jr, Henn S, Hestrosa F, Huynh C, McDonald C, Mls A, Overton ET, Ramgopal M, Rashbaum B, Ray G, Scarsella A, Yozvk J, McPhee F, L Z, Hughes E, Y PD, Novllo S, Ackerman P; ALLY-2 vestators. Daclatasv plus Sofosbuv for HCV Patnts Cofected wh H-1. N Engl J Med. 2015 Aug 20;373(8):714-25. do 10.1056/NEJMoa1503153. Epub 2015 Jul 21.
Determining the Sustained Virologic Response of Declatasvir in Egyptian Patients With Hepatitis C Virus Genotype 4
Subject
Language
English
Abstract
This is a prospective, cohort study in Faculty of Medicine, Zagazig University, Egypt. From June to December, 2016, investigators will follow up patients with chronic Hepatitis C virus genotype 4 receiving daclatasvir-sofosbuvir treatment regimen within the national program of Egyptian ministry of health and population. The primary outcomes are safety of the treatment and the sustained virologic response 12 weeks after discontinuation of therapy. For the secondary outcomes, investigators will measure the change in health related quality of life and investigate the genetic sequence of viral RNA of resistant patients.